Gender-affirming care is a term that has become politically charged in ways that obscure what it actually describes. In the clinical context, gender-affirming care refers to a set of practices — medical, psychological, and social — that support people whose gender identity differs from the sex they were assigned at birth. The practices vary widely by age, individual need, and what a patient and their providers decide together. Understanding what it actually is requires looking past the political debate to the clinical evidence.

What Gender-Affirming Care Includes

For children and early adolescents, gender-affirming care is primarily social: using chosen names and pronouns, allowing gender-nonconforming dress and presentation, providing access to affirming mental health support. There are no surgical interventions for prepubescent children. For adolescents who have entered puberty, puberty-delaying medications — the same medications used for precocious puberty for decades — may be discussed. These are reversible interventions that pause puberty, creating time for further evaluation without locking in irreversible changes. Hormone therapy — estrogen or testosterone — is a later step, typically beginning in mid-to-late adolescence with parental consent and ongoing clinical evaluation. Surgical interventions for minors are rare and, where they occur, almost always limited to chest surgery for transgender adolescent males, typically not performed before sixteen and only after sustained evaluation. For adults, the range of options expands. Adults may pursue hormone therapy, a variety of surgical procedures, voice training, and other interventions depending on their goals and circumstances. The model is informed consent: patients are provided information about expected effects, risks, and reversibility, and make decisions in partnership with their providers.

What the Research Shows

The evidence base for gender-affirming care has been building for decades. A 2020 study from the American Academy of Pediatrics reviewing outcomes data found that access to gender-affirming care was associated with significant reductions in depression, anxiety, and suicidality among transgender youth. Research from the Amsterdam Gender Clinic, one of the oldest and most extensively studied gender clinics in the world, has followed patients over decades, documenting that most adults who received gender-affirming care in adolescence reported satisfaction with the outcomes. A 2022 study published in the New England Journal of Medicine followed transgender and nonbinary adolescents receiving puberty blockers and found that those with access to treatment reported lower rates of depression and suicidal ideation at follow-up compared to baseline. These findings are consistent across multiple research groups in multiple countries. The claim that the evidence base is thin is often made in political contexts. The clinical consensus among major medical organizations — the American Medical Association, the American Academy of Pediatrics, the American Psychological Association, the Endocrine Society — is that gender-affirming care is evidence-based and that restricting access causes harm.

Who Gender-Affirming Care Is For

The majority of people who receive gender-affirming care are transgender adults. The political debate focuses disproportionately on minors, who represent a small fraction of people receiving this care. Among adolescents, access to care is governed by extensive evaluation processes, parental consent requirements, and ongoing clinical oversight. The image of children making irreversible decisions without adult involvement does not reflect how this care is actually delivered. Nonbinary people also access gender-affirming care, sometimes seeking interventions that do not correspond to a binary transition and sometimes not seeking medical intervention at all. Identity and medical care are related but distinct questions.

The Tangent About Comparative Medicine

It is worth noting that the same political culture that frames gender-affirming care as uniquely experimental regularly accepts medical interventions with comparable or weaker evidence bases. Antidepressants, for example, have a complex and contested evidence base for use in adolescents — including documented associations with increased suicidality in some age groups — but prescriptions for adolescents are not the subject of state-level legislation banning their use. The selectivity of concern about evidence and risk in this area is worth noticing. The people most affected by restrictions on gender-affirming care are not abstractions. They are adolescents and adults who, with their families and doctors, are trying to make decisions that allow them to live better lives. The research on what happens when they cannot access care — higher rates of depression, self-harm, and suicidal ideation — is not disputed by researchers with clinical expertise in this area.